Infections, Papillomavirus
Conditions
Brief summary
Human Papilloma viruses (HPV) are viruses that cause infections of the skin and genitals in men and women. Several types of HPV infection are transmitted by sexual activity and, in women, can infect the cervix (part of the uterus or womb). This infection, if it persists, can lead over a long period of time to cancer of the cervix in women. In collaboration with MedImmune Inc., GlaxoSmithKline Biologicals has developed a HPV vaccine against the oncogenic types HPV-16 and HPV-18 formulated with the adjuvant AS04. GSK Biologicals is also evaluating novel HPV vaccine formulations.This study will evaluate the immunogenicity and safety of a novel GSK Biologicals HPV vaccine in women 18-25 years of age at study start. Approximately 376 study subjects will receive the novel HPV vaccine or the control vaccine administered intramuscularly according to a 0-1-6 month schedule.
Interventions
BIOLOGICALHPV 16/18 L1 AS04
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
BIOLOGICALHPV-16/18/31/45 L1 AS04 Formulation 1
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
BIOLOGICALHPV-16/18/31/45 L1 AS04 Formulation 2
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
BIOLOGICALHPV-16/18/31/45 L1 AS04 Formulation 3
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
BIOLOGICALHPV-16/18/31/45 L1 AS04 Formulation 4
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
BIOLOGICALHPV-16/18/31/45 L1 AS04 Formulation 5
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
BIOLOGICALHPV-16/18/31/45 L1 AS04 Formulation 6
3 doses of 0.6 mL supplied as a liquid in individual pre-filled syringes administered intramuscularly in the deltoid muscle of the non-dominant arm, at Day 0, Month 1 and Month 6.
Sponsors
GlaxoSmithKline
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)
Masking description
This study was performed in a double-blinded manner. Blinding was maintained for all subjects and investigators and their study staff participating in this study with regard to the individual subject treatment (vaccine treatment) assignments allocated in this study. GSK personnel directly involved in the conduct of this study were also blinded to the subjects' treatment assignments.
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 25 Years
Healthy volunteers
Yes
Inclusion criteria
* A woman between, and including, 18 and 25 years of age at the time of the first vaccination * Written informed consent from the subject prior to enrolment * Subject must be free of obvious health problems * Subject must be of non-childbearing potential and have had no more than 6 lifetime sexual partners
Exclusion criteria
* Pregnant or breastfeeding * A woman planning to become pregnant or planning to discontinue contraceptive precautions during approximately the first nine months of the study (Month 0-8) * Known acute or chronic, clinically significant pulmonary, cardiovascular, neurologic, hepatic or renal functional abnormality * History of chronic condition(s) requiring treatment such as cancer, chronic hepatitis or kidney disease(s), diabetes, or autoimmune disease * Previous vaccination against human papillomavirus (HPV)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | At Month 7 | Seroconversion was defined as the appearance of anti-HPV-16 antibodies \[i.e. antibody titer greater than or equal to (≥) the cut-off value\] in the serum of subjects seronegative before vaccination. The cut-off value was 8 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL). |
| Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | At Month 7 | Seroconversion was defined as the appearance of anti-HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 7 EL.U/mL. |
| Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | At Month 7 | Anti-HPV-16 antibody titers were presented as Geometric Mean Titers (GMT) and expressed in EL.U/mL. |
| Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | At Month 7 | Anti-HPV-18 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | At Month 2 and Month 7 | Seroconversion was defined as the appearance of anti-HPV-31 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 59 EL.U/mL. |
| Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | At Month 2 and Month 7 | Seroconversion was defined as the appearance of anti-HPV-45 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 59 EL.U/mL. |
| Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | At Month 2 and Month 7 | Anti-HPV-31 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL. |
| Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | At Month 2 and Month 7 | Anti-HPV-45 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL. |
| Number of Subjects With Any and Grade 3 Solicited Local Symptoms | During the 7 day post-vaccination period following each dose and across doses | Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any solicited local symptom regardless of their intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activity. Grade 3 redness/swelling = redness/swelling above 50 millimeters (mm). All the reported local symptoms are considered related to the vaccination in the study. |
| Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | During the 7 day post-vaccination period following each dose and across doses | Assessed solicited general symptoms were arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash and urticaria. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to vaccination. Any Fever = axillary temperature greater than or equal to (≥) 37.5 degrees Celsius (°C). Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever greater than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to the vaccination. |
| Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | At Month 2 | Seroconversion was defined as the appearance of anti-HPV-16 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 8 EL.U/mL. |
| Number of Subjects With Any Serious Adverse Events (SAEs) | From Day 0 to Month 7 | SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination. |
| Number of Subjects With Any SAEs During the Extended Safety Follow-up | From Day 0 to Month 12 | SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination. |
| Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | From Day 0 to Month 12 | Outcomes of reported pregnancies were: Healthy baby, Spontaneous abortion, Elective abortion. |
| Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | From Day 0 up to Month 12 | NOCDs assessed include chronic diseases such as autoimmune disorders, diabetes, allergies also asthma and pathognomic signs/symptoms of these diseases. |
| Number of Subjects Reporting Medically Significant Conditions | From Day 0 up to Month 12 | Medically significant conditions are AEs prompting emergency room or physician visits that were not related to common diseases or routine visits for physical examination or vaccination, or SAEs that were not related to common diseases. |
| Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | At Month 2 and Month 7 | The parameters assessed were both biochemical (alanine aminotransferase = ALAT, creatinine = CREA, blood urea nitrogen = BUN) and haematological \[basophils = BAS, eosinophils = EOS, red blood cells = RBC, hematocrit = HCT, hemoglobin = HGB, leukocytes (white blood cells) = WBC, lymphocytes = LYM, monocytes = MONO, neutrophils = NEU and platelets = PLA\]. Abnormal values of a parameter at Months 2 and 7 are defined as below and above the normal ranges, as compared to the baseline status of the same parameter. |
| Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | During the 30-day post-vaccination period | An unsolicited adverse event (AE) was defined as any AE reported in addition to those solicited during the clinical study. Also, any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination. Grade 3 unsolicited AE = an AE that prevented normal, everyday activities. Related AE = an AE assessed by the investigator as causally related to the study vaccination. |
| Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | At Month 2 | Seroconversion was defined as the appearance of anti-HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 7 EL.U/mL. |
| Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | At Month 2 | Anti-HPV-16 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL. |
| Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | At Month 2 | Anti-HPV-18 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL. |
Countries
Belgium, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| HPV-16/18 Group Female subjects who received 3 doses of the HPV-16/18 L1 AS04 vaccine intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 88 |
| HPV-TETRA A Group Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 1 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 50 |
| HPV-TETRA B Group Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 2 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 49 |
| HPV-TETRA C Group Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 3 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 48 |
| HPV-TETRA D Group Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 4 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 48 |
| HPV-TETRA E Group Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 5 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 50 |
| HPV-TETRA F Group Female subjects who received 3 doses of the HPV-16/18/31/45 L1/AS04 vaccine, formulation 6 intramuscularly, into the deltoid of the non-dominant arm according to a 3-dose 0, 1, 6-month vaccination schedule. | 50 |
| Total | 383 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 |
|---|---|---|---|---|---|---|---|---|
| Overall Study | Lost to Follow-up | 4 | 4 | 1 | 1 | 1 | 4 | 0 |
| Overall Study | Migrated/moved from study area | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Overall Study | Non-serious AE | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Overall Study | Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 3 | 1 | 4 | 2 | 2 | 0 | 3 |
Baseline characteristics
| Characteristic | HPV-16/18 Group | HPV-TETRA A Group | HPV-TETRA B Group | HPV-TETRA C Group | HPV-TETRA D Group | HPV-TETRA E Group | HPV-TETRA F Group | Total |
|---|---|---|---|---|---|---|---|---|
| Age, Continuous | 20.9 Years STANDARD_DEVIATION 2.03 | 21.5 Years STANDARD_DEVIATION 2.18 | 21.2 Years STANDARD_DEVIATION 2.07 | 21.1 Years STANDARD_DEVIATION 2.09 | 21.4 Years STANDARD_DEVIATION 2.27 | 21.2 Years STANDARD_DEVIATION 2.26 | 20.7 Years STANDARD_DEVIATION 1.91 | 21.1 Years STANDARD_DEVIATION 2.1 |
| Race/Ethnicity, Customized American hispanic | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants | 2 Participants | 0 Participants | 5 Participants |
| Race/Ethnicity, Customized Arabic/north african | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Black | 1 Participants | 0 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 1 Participants | 6 Participants |
| Race/Ethnicity, Customized East/south east asian | 4 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 6 Participants |
| Race/Ethnicity, Customized Japanese | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race/Ethnicity, Customized Other, not specified | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 6 Participants |
| Race/Ethnicity, Customized South asian | 0 Participants | 0 Participants | 1 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants |
| Race/Ethnicity, Customized White/caucasian | 80 Participants | 50 Participants | 46 Participants | 46 Participants | 42 Participants | 44 Participants | 47 Participants | 355 Participants |
| Sex: Female, Male Female | 88 Participants | 50 Participants | 49 Participants | 48 Participants | 48 Participants | 50 Participants | 50 Participants | 383 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk |
|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 88 | 0 / 50 | 0 / 49 | 0 / 48 | 0 / 48 | 0 / 50 | 0 / 50 |
| other Total, other adverse events | 81 / 88 | 48 / 50 | 46 / 49 | 45 / 48 | 44 / 48 | 50 / 50 | 47 / 50 |
| serious Total, serious adverse events | 2 / 88 | 2 / 50 | 1 / 49 | 3 / 48 | 2 / 48 | 0 / 50 | 0 / 50 |
Outcome results
Primary
Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7
Anti-HPV-16 antibody titers were presented as Geometric Mean Titers (GMT) and expressed in EL.U/mL.
Time frame: At Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| HPV-16/18 Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 9086.1 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 5757.4 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 7897.7 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 7524.1 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 5986.4 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 8483.5 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 7 | 7605.0 EL.U/mL |
Primary
Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7
Anti-HPV-18 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL.
Time frame: At Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| HPV-16/18 Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 5184.5 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 3061.3 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 3640.2 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 3268.6 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 2998.5 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 3296.2 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 7 | 3056.0 EL.U/mL |
Primary
Number of Seroconverted Subjects for Anti-HPV-18 at Month 7
Seroconversion was defined as the appearance of anti-HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 7 EL.U/mL.
Time frame: At Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 59 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 30 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 37 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 34 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 27 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 33 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 7 | 36 Participants |
Primary
Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7
Seroconversion was defined as the appearance of anti-HPV-16 antibodies \[i.e. antibody titer greater than or equal to (≥) the cut-off value\] in the serum of subjects seronegative before vaccination. The cut-off value was 8 enzyme-linked immunosorbent assay (ELISA) units per milliliter (EL.U/mL).
Time frame: At Month 7
Population: The analysis was based on the According-to-Protocol (ATP) cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 62 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 27 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 31 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 23 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 33 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 28 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 | 33 Participants |
Secondary
Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2
Anti-HPV-16 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL.
Time frame: At Month 2
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| HPV-16/18 Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 3256.7 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 2718.9 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 2779.4 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 2915.5 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 2353.5 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 3202.3 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-16 Antibody Titers Assessed by ELISA at Month 2 | 2720.9 EL.U/mL |
Secondary
Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2
Anti-HPV-18 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL.
Time frame: At Month 2
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| HPV-16/18 Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 2530.1 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 1731.5 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 1875.9 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 2082.2 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 2048.8 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 2003.1 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-18 Antibody Titers Assessed by ELISA at Month 2 | 1820.0 EL.U/mL |
Secondary
Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7
Anti-HPV-31 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL.
Time frame: At Month 2 and Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| HPV-16/18 Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 232.8 EL.U/mL |
| HPV-16/18 Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 920.5 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 3694.6 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 7909.0 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 6271.3 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 14957.8 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 4570.7 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 9688.5 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 5114.8 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 11768.3 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 4846.7 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 9139.9 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 5627.6 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-31 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 12652.0 EL.U/mL |
Secondary
Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7
Anti-HPV-45 antibody titers were presented as Geometric Mean Titers and expressed in EL.U/mL.
Time frame: At Month 2 and Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| HPV-16/18 Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 915.7 EL.U/mL |
| HPV-16/18 Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 317.4 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 4719.4 EL.U/mL |
| HPV-TETRA A Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 1550.7 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 2613.9 EL.U/mL |
| HPV-TETRA B Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 7923.1 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 5851.8 EL.U/mL |
| HPV-TETRA C Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 1893.7 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 6027.6 EL.U/mL |
| HPV-TETRA D Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 2113.3 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 2217.4 EL.U/mL |
| HPV-TETRA E Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 6266.4 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 7 | 6149.5 EL.U/mL |
| HPV-TETRA F Group | Anti-HPV-45 Antibody Titers Assessed by ELISA at Months 2 and 7 | Month 2 | 2208.9 EL.U/mL |
Secondary
Number of Seroconverted Subjects for Anti-HPV-16 at Month 2
Seroconversion was defined as the appearance of anti-HPV-16 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 8 EL.U/mL.
Time frame: At Month 2
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 62 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 27 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 31 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 23 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 33 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 28 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-16 at Month 2 | 33 Participants |
Secondary
Number of Seroconverted Subjects for Anti-HPV-18 at Month 2
Seroconversion was defined as the appearance of anti-HPV-18 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 7 EL.U/mL.
Time frame: At Month 2
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 59 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 30 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 37 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 34 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 27 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 33 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-18 at Month 2 | 36 Participants |
Secondary
Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7
Seroconversion was defined as the appearance of anti-HPV-31 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 59 EL.U/mL.
Time frame: At Month 2 and Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 54 Participants |
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 61 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 32 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 32 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 37 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 37 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 29 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 29 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 31 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 31 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 30 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 30 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 2 | 36 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-31 at Months 2 and 7 | Month 7 | 36 Participants |
Secondary
Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7
Seroconversion was defined as the appearance of anti-HPV-45 antibodies (i.e. antibody titer ≥ cut-off value) in the serum of subjects seronegative before vaccination. The cut-off value was 59 EL.U/mL.
Time frame: At Month 2 and Month 7
Population: The analysis was based on the ATP cohort for immunogenicity, which included all evaluable subjects with available data concerning immunogenicity outcome measures, who were seronegative before vaccination and for whom assay results were available for antibodies against at least one study vaccine antigen component after vaccination.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 56 Participants |
| HPV-16/18 Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 54 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 33 Participants |
| HPV-TETRA A Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 33 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 31 Participants |
| HPV-TETRA B Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 31 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 27 Participants |
| HPV-TETRA C Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 27 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 32 Participants |
| HPV-TETRA D Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 32 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 34 Participants |
| HPV-TETRA E Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 34 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 2 | 35 Participants |
| HPV-TETRA F Group | Number of Seroconverted Subjects for Anti-HPV-45 at Months 2 and 7 | Month 7 | 35 Participants |
Secondary
Number of Subjects Reporting Medically Significant Conditions
Medically significant conditions are AEs prompting emergency room or physician visits that were not related to common diseases or routine visits for physical examination or vaccination, or SAEs that were not related to common diseases.
Time frame: From Day 0 up to Month 12
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Subjects Reporting Medically Significant Conditions | 2 Participants |
| HPV-TETRA A Group | Number of Subjects Reporting Medically Significant Conditions | 1 Participants |
| HPV-TETRA B Group | Number of Subjects Reporting Medically Significant Conditions | 1 Participants |
| HPV-TETRA C Group | Number of Subjects Reporting Medically Significant Conditions | 2 Participants |
| HPV-TETRA D Group | Number of Subjects Reporting Medically Significant Conditions | 2 Participants |
| HPV-TETRA E Group | Number of Subjects Reporting Medically Significant Conditions | 0 Participants |
| HPV-TETRA F Group | Number of Subjects Reporting Medically Significant Conditions | 0 Participants |
Secondary
Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs)
NOCDs assessed include chronic diseases such as autoimmune disorders, diabetes, allergies also asthma and pathognomic signs/symptoms of these diseases.
Time frame: From Day 0 up to Month 12
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 5 Participants |
| HPV-TETRA A Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 6 Participants |
| HPV-TETRA C Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects Reporting New Onset of Chronic Diseases (NOCDs) | 2 Participants |
Secondary
Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies
Outcomes of reported pregnancies were: Healthy baby, Spontaneous abortion, Elective abortion.
Time frame: From Day 0 to Month 12
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 1 Participants |
| HPV-16/18 Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 0 Participants |
| HPV-16/18 Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 0 Participants |
| HPV-TETRA A Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 0 Participants |
| HPV-TETRA A Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 0 Participants |
| HPV-TETRA A Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 0 Participants |
| HPV-TETRA B Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 0 Participants |
| HPV-TETRA B Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 2 Participants |
| HPV-TETRA B Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 0 Participants |
| HPV-TETRA C Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 0 Participants |
| HPV-TETRA C Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 1 Participants |
| HPV-TETRA C Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 0 Participants |
| HPV-TETRA D Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 1 Participants |
| HPV-TETRA D Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 0 Participants |
| HPV-TETRA D Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 0 Participants |
| HPV-TETRA E Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 1 Participants |
| HPV-TETRA E Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 0 Participants |
| HPV-TETRA E Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 0 Participants |
| HPV-TETRA F Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Elective abortion | 0 Participants |
| HPV-TETRA F Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Spontaneous abortion | 0 Participants |
| HPV-TETRA F Group | Number of Subjects Reporting Pregnancies and Outcomes of Reported Pregnancies | Healthy baby | 2 Participants |
Secondary
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of any solicited local symptom regardless of their intensity grade. Grade 3 pain = significant pain at rest, that prevented normal every day activity. Grade 3 redness/swelling = redness/swelling above 50 millimeters (mm). All the reported local symptoms are considered related to the vaccination in the study.
Time frame: During the 7 day post-vaccination period following each dose and across doses
Population: The analysis was based on the Total Vaccinated Cohort (TVC), which included all subjects with at least one vaccine administration documented, for whom data were available at the specified time point and had symptom sheets completed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 81 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 6 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 70 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 68 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 7 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 81 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 10 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 20 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 21 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 22 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 36 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 17 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 17 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 23 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 33 Participants |
| HPV-16/18 Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 6 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 42 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 17 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 22 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 6 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 45 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 48 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 14 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 12 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 40 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 10 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 10 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 28 Participants |
| HPV-TETRA A Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 18 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 6 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 12 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 5 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 12 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 9 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 15 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 44 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 8 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 40 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 46 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 8 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 33 Participants |
| HPV-TETRA B Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 40 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 10 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 45 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 14 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 12 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 10 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 15 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 18 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 22 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 8 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 6 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 11 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 45 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 6 Participants |
| HPV-TETRA C Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 42 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 15 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 21 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 40 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 13 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 16 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 14 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 11 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 44 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 7 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 15 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 5 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 37 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 6 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 24 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 44 Participants |
| HPV-TETRA D Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 15 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 22 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 27 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 18 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 14 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 12 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 18 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 50 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 43 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 6 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 49 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 16 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 40 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 4 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 13 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 5 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 1 | 11 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 1 | 7 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Across doses | 19 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Across doses | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 3 | 11 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 1 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 1 | 46 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Across doses | 25 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 3 | 39 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Across doses | 12 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 3 | 13 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 2 | 6 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 1 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Across doses | 47 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Redness - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 2 | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Across doses | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Swelling - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Redness - Dose 2 | 13 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Swelling - Dose 1 | 9 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Grade 3 Pain - Dose 3 | 7 Participants |
| HPV-TETRA F Group | Number of Subjects With Any and Grade 3 Solicited Local Symptoms | Any Pain - Dose 2 | 45 Participants |
Secondary
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were arthralgia, fatigue, fever, gastrointestinal symptoms, headache, myalgia, rash and urticaria. Any = occurrence of any solicited general symptom regardless of intensity grade or relationship to vaccination. Any Fever = axillary temperature greater than or equal to (≥) 37.5 degrees Celsius (°C). Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever greater than (\>) 39.0°C. Related = general symptom assessed by the investigator as causally related to the vaccination.
Time frame: During the 7 day post-vaccination period following each dose and across doses
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented, for whom data were available at the specified time point and had symptom sheets completed.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 6 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 36 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 11 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 5 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 17 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 6 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 7 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 16 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 14 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 14 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 32 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 8 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 25 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 5 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 45 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 8 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 10 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 25 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 5 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 15 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 7 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 32 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 20 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 10 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 18 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 42 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 20 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 21 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 14 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 54 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 18 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 12 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 28 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 24 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 22 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 32 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 26 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 19 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 37 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 5 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 12 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 12 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 10 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 24 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 17 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 14 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 4 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 6 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 5 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 10 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 4 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 13 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 12 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 23 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 13 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 19 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 14 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 16 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 15 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 33 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 16 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 4 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 28 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 18 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 4 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 4 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 10 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 4 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 10 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 6 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 5 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 15 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 8 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 11 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 8 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 17 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 6 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 13 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 16 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 9 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 9 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 11 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 13 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 5 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 23 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 24 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 4 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 15 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 12 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 19 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 5 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 10 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 8 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 15 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 9 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 18 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 4 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 4 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 11 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 16 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 30 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 9 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 11 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 6 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 8 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 6 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 16 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 24 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 5 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 5 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 9 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 19 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 14 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 8 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 18 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 7 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 10 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 18 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 13 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 20 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 14 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 5 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 32 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 22 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 5 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 8 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 14 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 9 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 9 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 16 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 8 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 16 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 8 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 31 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 5 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 10 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 24 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 6 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 6 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 6 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 6 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 11 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 22 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 8 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 8 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 15 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 5 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 6 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 12 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 25 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 17 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 12 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 11 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 10 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 15 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 8 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 11 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 14 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 7 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 8 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 20 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 10 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 17 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 22 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 14 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 13 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 6 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 19 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 6 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 11 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 9 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 17 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 19 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 5 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 9 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 5 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 27 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 22 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 21 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 16 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 22 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 16 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 34 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 5 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 27 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 4 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 10 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 5 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 10 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 8 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 7 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 17 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 10 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 29 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 18 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 19 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 14 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 18 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 15 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 33 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 5 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 25 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 14 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 10 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 5 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 4 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 7 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 6 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 19 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 14 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 2 | 19 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 1 | 9 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 1 | 13 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 2 | 5 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Across doses | 11 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Across doses | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Across doses | 18 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 3 | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 3 | 8 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 3 | 6 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 2 | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 2 | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Gastrointestinal - Dose 1 | 7 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Gastrointestinal - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Gastrointestinal - Dose 1 | 13 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Across doses | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Across doses | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Across doses | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 1 | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 3 | 7 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 2 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 1 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Across doses | 15 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 2 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fever - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fever - Dose 1 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fever - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Across doses | 27 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Across doses | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Across doses | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Across doses | 31 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 3 | 14 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 3 | 20 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Across doses | 13 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 2 | 11 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 2 | 16 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Fatigue - Dose 1 | 20 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Fatigue - Dose 1 | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 1 | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Fatigue - Dose 1 | 25 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Across doses | 9 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Across doses | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Across doses | 11 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 3 | 5 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Across doses | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 1 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 3 | 7 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 2 | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 2 | 5 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Across doses | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Arthralgia - Dose 1 | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Arthralgia - Dose 1 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Artharlgia - Dose 1 | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 3 | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Across doses | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Across doses | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Rash - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Across doses | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Across doses | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Urticaria - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Urticaria - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Urticaria - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Myalgia - Dose 1 | 9 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 1 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 1 | 10 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Across doses | 21 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Across doses | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Rash - Dose 3 | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Myalgia - Dose 2 | 7 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Across doses | 27 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 3 | 13 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 3 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Any Headache - Dose 3 | 18 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Related Headache - Dose 2 | 11 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Rash - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Myalgia - Dose 2 | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms | Grade 3 Headache - Dose 2 | 2 Participants |
Secondary
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
An unsolicited adverse event (AE) was defined as any AE reported in addition to those solicited during the clinical study. Also, any solicited symptom with onset outside the specified period of follow-up for solicited symptoms was reported as an unsolicited adverse event. Any is defined as the occurrence of any unsolicited AE irrespective of its intensity grade and relationship to vaccination. Grade 3 unsolicited AE = an AE that prevented normal, everyday activities. Related AE = an AE assessed by the investigator as causally related to the study vaccination.
Time frame: During the 30-day post-vaccination period
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 17 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 60 Participants |
| HPV-16/18 Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 14 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 5 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 31 Participants |
| HPV-TETRA A Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 16 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 7 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 34 Participants |
| HPV-TETRA B Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 8 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 25 Participants |
| HPV-TETRA C Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 6 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 32 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 5 Participants |
| HPV-TETRA D Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 9 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 36 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 6 Participants |
| HPV-TETRA E Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 8 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Any AEs | 29 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Grade 3 AEs | 8 Participants |
| HPV-TETRA F Group | Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs) | Related AEs | 9 Participants |
Secondary
Number of Subjects With Any SAEs During the Extended Safety Follow-up
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.
Time frame: From Day 0 to Month 12
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any SAEs During the Extended Safety Follow-up | 0 Participants |
Secondary
Number of Subjects With Any Serious Adverse Events (SAEs)
SAEs assessed include medical occurrences that resulted in death, were life-threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity or were a congenital anomaly/birth defect in the offspring of a study subject. Any was defined as occurrence of any symptom regardless of intensity grade or relation to vaccination.
Time frame: From Day 0 to Month 7
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| HPV-16/18 Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Any Serious Adverse Events (SAEs) | 0 Participants |
Secondary
Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters
The parameters assessed were both biochemical (alanine aminotransferase = ALAT, creatinine = CREA, blood urea nitrogen = BUN) and haematological \[basophils = BAS, eosinophils = EOS, red blood cells = RBC, hematocrit = HCT, hemoglobin = HGB, leukocytes (white blood cells) = WBC, lymphocytes = LYM, monocytes = MONO, neutrophils = NEU and platelets = PLA\]. Abnormal values of a parameter at Months 2 and 7 are defined as below and above the normal ranges, as compared to the baseline status of the same parameter.
Time frame: At Month 2 and Month 7
Population: The analysis was based on the TVC, which included all subjects with at least one vaccine administration documented for whom data were available at the specified time points.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 6 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 5 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 68 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 70 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 69 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 80 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 78 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 76 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 83 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 78 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 5 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 73 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 78 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 70 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 63 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 69 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 73 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 65 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 67 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 71 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 71 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 74 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 78 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 63 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 69 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 7 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 4 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-16/18 Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 35 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 6 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 37 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 6 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 35 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 42 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 35 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 44 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 42 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 34 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 38 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 36 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA A Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 36 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 36 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 42 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 39 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 34 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 34 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 4 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA B Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 38 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 32 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 36 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 44 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 44 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 31 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 37 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 3 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA C Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 4 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 38 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 36 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 3 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 39 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 39 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 35 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA D Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 45 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 37 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 35 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 42 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 45 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 41 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 47 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 38 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 46 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 40 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 44 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 47 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 47 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 48 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 37 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA E Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 2) | 45 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 2) | 46 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 7) | 39 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Normal (Month 7) | 45 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 7) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 2) | 37 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 2) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 7) | 42 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 7) | 37 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | ALAT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Normal (Month 7) | 44 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 7) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Normal (Month 2) | 43 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 2) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | CREA, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | BAS, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 2) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Normal (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Normal (Month 2) | 40 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Above (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | NEU, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Normal (Month 7) | 39 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 2) | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | MONO, Normal (pre-vacc) - Below (Month 2) | 5 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Below (pre-vacc) - Normal (Month 2) | 3 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Missing (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 7) | 43 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | LYM, Normal (pre-vacc) - Normal (Month 7) | 39 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Below (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Above (pre-vacc) - Normal (Month 7) | 4 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Above (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 7) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Above (pre-vacc) - Normal (Month 2) | 2 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Normal (Month 7) | 39 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | HCT, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Normal (pre-vacc) - Normal (Month 2) | 41 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | WBC, Below (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Below (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Normal (Month 7) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Below (pre-vacc) - Normal (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 7) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Above (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Normal (Month 7) | 42 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Missing (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Normal (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Above (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | EOS, Above (pre-vacc) - Above (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | RBC, Below (pre-vacc) - Normal (Month 2) | 1 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Below (Month 2) | 0 Participants |
| HPV-TETRA F Group | Number of Subjects With Clinically Relevant Abnormalities in Biochemical and Haematological Parameters | PLA, Below (pre-vacc) - Normal (Month 2) | 0 Participants |